Today, Dante Labs launched its Global Epilepsy Whole Genome Study, which will sequence 1,000 patients diagnosed with epilepsy over the next nine months, further advancing the research and development of gene therapies for epilepsy.
The study was first advocated by Epilepsy Awareness Day at Disneyland (EADDL), which will also lead the selection of epilepsy patients for this project.
“Brad and Candy Levy at the Epilepsy Awareness Day at Disneyland have done an amazing job supporting epilepsy patients and their families across the United States and the world,” said Dante Labs CEO Andrea Riposati. “We are excited to dedicate resources to the study of epilepsy.”